PURPOSE: Mycobacterium leprae exploits complement activation and opsonophagocytosis to infect phagocytes. M-ficolin is encoded by the FCN1 gene and initiates the lectin pathway on monocyte surfaces. We investigated FCN1 promoter polymorphisms that could be responsible for the high interindividual variability of M-ficolin levels and for modulating leprosy susceptibility. METHODS: We genotyped rs2989727 (-1981 G > A), rs28909068 (-791 G > A), rs10120023 (-542 G > A), rs17039495 (-399 G > A), rs28909976 (-271IndelT), rs10117466 (-144C > A) and rs10858293 (+33 T > G) in 400 controls and 315 leprosy patients from Southern Brazil, and in 296 Danish healthy individuals with known M-ficolin levels. RESULTS: Ten haplotypes were identified with sequence-specific PCR and/or haplotype-specific sequencing. We found evidence for a protective codominant additive effect of FCN1*-542A-144C with leprosy in Euro-Brazilians (P=0.003, PBf =0.021, OR=0.243 [CI95% =0.083-0.71]), which was independent of age, ethnic group and gender effects (P=0.029). There was a trend for a positive association of the -399A variant in Afro-Brazilians (P=0.022, PBf =0.154, OR=4.151 [CI95% =1.115-15.454], as well as for a negative association of the FCN1*3A haplotype with lepromatous leprosy, compared with less severe forms of the disease (P=0.016, PBf =0.112, OR=0.324 [CI95% =0.123-0.858]). Danish individuals with this haplotype presented M-ficolin levels higher than the population average of circa 1,000 ng/ml, and -542A-144C, which is able to modify the recognition of transcription factors in silico, occurred in individuals with levels under the 25 percentil (P=0.031). CONCLUSIONS: Our data provide the first evidence that FCN1 polymorphisms are associated with leprosy. M-ficolin may represent a novel key to understand the immunopathogenesis of M. leprae infection.
PURPOSE: Mycobacterium leprae exploits complement activation and opsonophagocytosis to infect phagocytes. M-ficolin is encoded by the FCN1 gene and initiates the lectin pathway on monocyte surfaces. We investigated FCN1 promoter polymorphisms that could be responsible for the high interindividual variability of M-ficolin levels and for modulating leprosy susceptibility. METHODS: We genotyped rs2989727 (-1981 G > A), rs28909068 (-791 G > A), rs10120023 (-542 G > A), rs17039495 (-399 G > A), rs28909976 (-271IndelT), rs10117466 (-144C > A) and rs10858293 (+33 T > G) in 400 controls and 315 leprosypatients from Southern Brazil, and in 296 Danish healthy individuals with known M-ficolin levels. RESULTS: Ten haplotypes were identified with sequence-specific PCR and/or haplotype-specific sequencing. We found evidence for a protective codominant additive effect of FCN1*-542A-144C with leprosy in Euro-Brazilians (P=0.003, PBf =0.021, OR=0.243 [CI95% =0.083-0.71]), which was independent of age, ethnic group and gender effects (P=0.029). There was a trend for a positive association of the -399A variant in Afro-Brazilians (P=0.022, PBf =0.154, OR=4.151 [CI95% =1.115-15.454], as well as for a negative association of the FCN1*3A haplotype with lepromatous leprosy, compared with less severe forms of the disease (P=0.016, PBf =0.112, OR=0.324 [CI95% =0.123-0.858]). Danish individuals with this haplotype presented M-ficolin levels higher than the population average of circa 1,000 ng/ml, and -542A-144C, which is able to modify the recognition of transcription factors in silico, occurred in individuals with levels under the 25 percentil (P=0.031). CONCLUSIONS: Our data provide the first evidence that FCN1 polymorphisms are associated with leprosy. M-ficolin may represent a novel key to understand the immunopathogenesis of M. leprae infection.
Authors: Valeria L Runza; Thomas Hehlgans; Bernd Echtenacher; Ulrich Zähringer; Wilhelm J Schwaeble; Daniela N Männel Journal: J Endotoxin Res Date: 2006
Authors: Ping Xu; Mark Crawford; Michael Way; Jasminka Godovac-Zimmermann; Anthony W Segal; Marko Radulovic Journal: Proteomics Date: 2009-04 Impact factor: 3.984
Authors: Gabriela I Gomes; Edilbert P Nahn; Rose K R G Santos; Wilmar D Da Silva; Thereza L Kipnis Journal: Am J Trop Med Hyg Date: 2008-04 Impact factor: 2.345
Authors: B Vander Cruyssen; L Nuytinck; L Boullart; D Elewaut; W Waegeman; M Van Thielen; E De Meester; K Lebeer; R Rossau; F De Keyser Journal: Rheumatology (Oxford) Date: 2007-12 Impact factor: 7.580
Authors: Angelica B W Boldt; Iara J Messias-Reason; Bertrand Lell; Saadou Issifou; Maria Lucia Alves Pedroso; Peter G Kremsner; Jürgen F J Kun Journal: Malar J Date: 2009-05-11 Impact factor: 2.979
Authors: Ninette Genster; Olga Østrup; Camilla Schjalm; Tom Eirik Mollnes; Jack B Cowland; Peter Garred Journal: Sci Rep Date: 2017-06-20 Impact factor: 4.379
Authors: Gabriela Canalli Kretzschmar; Luana Caroline Oliveira; Renato Mitsunori Nisihara; Thirumalaisamy P Velavan; Sérvio Túlio Stinghen; Ewalda R S Stahlke; Maria Luiza Petzl-Erler; Iara José T de Messias-Reason; Angelica Beate Winter Boldt Journal: PLoS Negl Trop Dis Date: 2018-08-09
Authors: Christian Gytz Ammitzbøll; Troels Rønn Kjær; Rudi Steffensen; Kristian Stengaard-Pedersen; Hans Jørgen Nielsen; Steffen Thiel; Martin Bøgsted; Jens Christian Jensenius Journal: PLoS One Date: 2012-11-28 Impact factor: 3.240
Authors: Angelica Beate Winter Boldt; Isabela Goeldner; Ewalda R S Stahlke; Steffen Thiel; Jens Christian Jensenius; Iara José Taborda de Messias-Reason Journal: PLoS One Date: 2013-07-30 Impact factor: 3.240
Authors: Stefanie Epp Boschmann; Angelica Beate Boldt; Ilíada Rainha de Souza; Maria Luiza Petzl-Erler; Iara Jose Messias-Reason Journal: Med Princ Pract Date: 2015-11-14 Impact factor: 1.927